TapewireFind a company

person · Reporting owner

Morrissey Joseph T. Jr.

Disclosed activity across 1 company

Tapewire entity
54159
SEC CIK
0001859805

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Organon & Co.OGN · Entity 4115Interim CEOMarch 31, 2026April 02, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Organon & Co.

Report date March 31, 2026 · Filed April 02, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect123,122.923 Ending reported balance After 2026-03-31 transaction · row 4
4 source rows · reconciled sequence

Row 1 · 2026-03-31 · Exercise / conversion · Acquired 7,795 · Balance 113,338.923

Row 2 · 2026-03-31 · Tax withholding · Disposed 2,221 · Balance 111,117.923

F1: This price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded.

Row 3 · 2026-03-31 · Exercise / conversion · Acquired 16,789 · Balance 127,906.923

Row 4 · 2026-03-31 · Tax withholding · Disposed 4,784 · Balance 123,122.923

F1: This price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect333,889 Reported balance After 2026-03-31 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2026-03-31 · Grant · Acquired 333,889 · Balance 333,889

F2: On March 31, 2026, the Reporting Person was granted 333,889 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect0 Reported balance After 2026-03-31 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2026-03-31 · Exercise / conversion · Disposed 7,795 · Balance 0

F3: Each RSU represents a contingent right to receive one share of Organon common stock.

F4: On March 31, 2023, the Reporting Person was granted 23,384 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect33,580 Reported balance After 2026-03-31 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2026-03-31 · Exercise / conversion · Disposed 16,789 · Balance 33,580

F3: Each RSU represents a contingent right to receive one share of Organon common stock.

F5: On March 31, 2025, the Reporting Person was granted 50,369 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028.

Filing footnotes · ownership attribution and instrument terms

F1: This price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded.

F2: On March 31, 2026, the Reporting Person was granted 333,889 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029.

F3: Each RSU represents a contingent right to receive one share of Organon common stock.

F4: On March 31, 2023, the Reporting Person was granted 23,384 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026.

F5: On March 31, 2025, the Reporting Person was granted 50,369 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
March 31, 2026 Filed Apr 2, 2026 20:02 UTC Organon & Co. OGN · Entity 4115 Exercise / conversionRestricted Stock Units · Derivative 16,789 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-023127 · wk-form4_1775160158.xml · derivative · entry 7

Morrissey Joseph T. Jr. · CIK 0001859805 · Interim CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,580

Underlying: Common Stock · 16,789 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Organon common stock.

F5 · derivative.exercise_date: On March 31, 2025, the Reporting Person was granted 50,369 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028.

F5 · derivative.expiration_date: On March 31, 2025, the Reporting Person was granted 50,369 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028.

Read SEC document
March 31, 2026 Filed Apr 2, 2026 20:02 UTC Organon & Co. OGN · Entity 4115 Exercise / conversionRestricted Stock Units · Derivative 7,795 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-023127 · wk-form4_1775160158.xml · derivative · entry 6

Morrissey Joseph T. Jr. · CIK 0001859805 · Interim CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,795 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Organon common stock.

F4 · derivative.exercise_date: On March 31, 2023, the Reporting Person was granted 23,384 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026.

F4 · derivative.expiration_date: On March 31, 2023, the Reporting Person was granted 23,384 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026.

Read SEC document
March 31, 2026 Filed Apr 2, 2026 20:02 UTC Organon & Co. OGN · Entity 4115 GrantRestricted Stock Units · Derivative 333,889 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-023127 · wk-form4_1775160158.xml · derivative · entry 5

Morrissey Joseph T. Jr. · CIK 0001859805 · Interim CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 333,889

Underlying: Common Stock · 333,889 shares

Expires not disclosed

F2 · derivative.exercise_price: On March 31, 2026, the Reporting Person was granted 333,889 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029.

F2 · derivative.exercise_date: On March 31, 2026, the Reporting Person was granted 333,889 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029.

F2 · derivative.expiration_date: On March 31, 2026, the Reporting Person was granted 333,889 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029.

Read SEC document
March 31, 2026 Filed Apr 2, 2026 20:02 UTC Organon & Co. OGN · Entity 4115 Tax withholdingCommon Stock 4,784 $5.70 $27,268.80
Disclosure

SEC source: 0001628280-26-023127 · wk-form4_1775160158.xml · nonDerivative · entry 4

Morrissey Joseph T. Jr. · CIK 0001859805 · Interim CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 123,122.923

F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded.

Read SEC document
March 31, 2026 Filed Apr 2, 2026 20:02 UTC Organon & Co. OGN · Entity 4115 Exercise / conversionCommon Stock 16,789 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-023127 · wk-form4_1775160158.xml · nonDerivative · entry 3

Morrissey Joseph T. Jr. · CIK 0001859805 · Interim CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 127,906.923

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 31, 2026 Filed Apr 2, 2026 20:02 UTC Organon & Co. OGN · Entity 4115 Tax withholdingCommon Stock 2,221 $5.70 $12,659.70
Disclosure

SEC source: 0001628280-26-023127 · wk-form4_1775160158.xml · nonDerivative · entry 2

Morrissey Joseph T. Jr. · CIK 0001859805 · Interim CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 111,117.923

F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded.

Read SEC document
March 31, 2026 Filed Apr 2, 2026 20:02 UTC Organon & Co. OGN · Entity 4115 Exercise / conversionCommon Stock 7,795 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-023127 · wk-form4_1775160158.xml · nonDerivative · entry 1

Morrissey Joseph T. Jr. · CIK 0001859805 · Interim CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 113,338.923

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 29, 2026 Filed Mar 31, 2026 20:05 UTC Organon & Co. OGN · Entity 4115 Exercise / conversionRestricted Stock Units · Derivative 9,752 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-022368 · wk-form4_1774987546.xml · derivative · entry 3

Morrissey Joseph T. Jr. · CIK 0001859805 · Interim CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,752

Underlying: Common Stock · 9,752 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Organon common stock.

F3 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027.

F3 · derivative.expiration_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027.

Read SEC document
March 29, 2026 Filed Mar 31, 2026 20:05 UTC Organon & Co. OGN · Entity 4115 Tax withholdingCommon Stock 2,779 $5.84 $16,229.36
Disclosure

SEC source: 0001628280-26-022368 · wk-form4_1774987546.xml · nonDerivative · entry 2

Morrissey Joseph T. Jr. · CIK 0001859805 · Interim CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,543.923

F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 27, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded.

Read SEC document
March 29, 2026 Filed Mar 31, 2026 20:05 UTC Organon & Co. OGN · Entity 4115 Exercise / conversionCommon Stock 9,752 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-022368 · wk-form4_1774987546.xml · nonDerivative · entry 1

Morrissey Joseph T. Jr. · CIK 0001859805 · Interim CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,322.923

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 27, 2026 Filed Mar 3, 2026 23:56 UTC Organon & Co. OGN · Entity 4115 Tax withholdingCommon Stock 2,216 $7.23 $16,021.68
Disclosure

SEC source: 0001628280-26-014211 · wk-form4_1772582201.xml · nonDerivative · entry 4

Morrissey Joseph T. Jr. · CIK 0001859805 · Interim CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 98,570.923

F3 · balance_after: Includes the addition of 1,938.068 shares of Common Stock acquired from dividend equivalents net of withholding tax not previously required to be reported.

Read SEC document
February 27, 2026 Filed Mar 3, 2026 23:56 UTC Organon & Co. OGN · Entity 4115 GrantCommon Stock 7,777 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-014211 · wk-form4_1772582201.xml · nonDerivative · entry 3

Morrissey Joseph T. Jr. · CIK 0001859805 · Interim CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 98,848.855

F2 · shares: Represents the shares of Common Stock released to cover the dividend equivalents earned on the PSUs released above.

Read SEC document
February 27, 2026 Filed Mar 3, 2026 23:56 UTC Organon & Co. OGN · Entity 4115 Tax withholdingCommon Stock 8,054 $7.17 $57,747.18
Disclosure

SEC source: 0001628280-26-014211 · wk-form4_1772582201.xml · nonDerivative · entry 2

Morrissey Joseph T. Jr. · CIK 0001859805 · Interim CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 91,071.855

Read SEC document
February 27, 2026 Filed Mar 3, 2026 23:56 UTC Organon & Co. OGN · Entity 4115 GrantCommon Stock 27,564 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-014211 · wk-form4_1772582201.xml · nonDerivative · entry 1

Morrissey Joseph T. Jr. · CIK 0001859805 · Interim CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 99,125.855

F1 · shares: Represents shares of Organon & Co. common stock ("Common Stock") for performance share units ("PSUs") granted to the reporting person on August 11, 2023 under the Organon & Co. 2023 Incentive Stock Plan. The performance-vesting restrictions with respect to these shares were released upon certification of performance goal attainment by the Talent Committee of Organon's Board of Directors.

Read SEC document
November 13, 2025 Filed Nov 17, 2025 21:04 UTC Organon & Co. OGN · Entity 4115 GrantRestricted Stock Units · Derivative 131,233 $0.00 $0.00
Disclosure

SEC source: 0001628280-25-052590 · wk-form4_1763413454.xml · derivative · entry 1

Morrissey Joseph T. Jr. · CIK 0001859805 · Interim CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 131,233

Underlying: Common Stock · 131,233 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") converts into one share of Organon & Co. ("Organon") common stock.

F2 · derivative.exercise_date: The Reporting Person was granted RSUs on November 13, 2025 (which was the close of business on the third business day following the release of Organon's earnings for the quarter ended September 30, 2025, on November 10, 2025). These RSUs vest and become exercisable in three equal installments on November 13, 2026, November 13, 2027, and November 13, 2028.

F2 · derivative.expiration_date: The Reporting Person was granted RSUs on November 13, 2025 (which was the close of business on the third business day following the release of Organon's earnings for the quarter ended September 30, 2025, on November 10, 2025). These RSUs vest and become exercisable in three equal installments on November 13, 2026, November 13, 2027, and November 13, 2028.

Read SEC document
March 31, 2025 Filed Apr 2, 2025 21:33 UTC Organon & Co. OGN · Entity 4115 Exercise / conversionRestricted Stock Units · Derivative 3,937 $0.00 $0.00
Disclosure

SEC source: 0001859805-25-000004 · wk-form4_1743629588.xml · derivative · entry 11

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,937 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock.

F7 · derivative.exercise_date: On March 31, 2022, RSUs were awarded and on March 31, 2025, the final third of these RSUs vested.

F7 · derivative.expiration_date: On March 31, 2022, RSUs were awarded and on March 31, 2025, the final third of these RSUs vested.

Read SEC document
March 31, 2025 Filed Apr 2, 2025 21:33 UTC Organon & Co. OGN · Entity 4115 Exercise / conversionRestricted Stock Units · Derivative 7,795 $0.00 $0.00
Disclosure

SEC source: 0001859805-25-000004 · wk-form4_1743629588.xml · derivative · entry 10

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,795

Underlying: Common Stock · 7,795 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock.

F6 · derivative.exercise_date: On March 31, 2023, RSUs were awarded and on March 31, 2025, one-third of these RSUs vested with the remaining RSUs to vest on March 31, 2026.

F6 · derivative.expiration_date: On March 31, 2023, RSUs were awarded and on March 31, 2025, one-third of these RSUs vested with the remaining RSUs to vest on March 31, 2026.

Read SEC document
March 31, 2025 Filed Apr 2, 2025 21:33 UTC Organon & Co. OGN · Entity 4115 Exercise / conversionRestricted Stock Units · Derivative 9,751 $0.00 $0.00
Disclosure

SEC source: 0001859805-25-000004 · wk-form4_1743629588.xml · derivative · entry 9

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,504

Underlying: Common Stock · 9,751 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock.

F5 · derivative.exercise_date: On March 29, 2024, RSUs were granted and on March 29, 2025, one-third of these RSUs vested, with the remaining RSUs to vest on March 29, 2026, and March 29, 2027. Since the first anniversary of the date of grant was on Saturday, March 29, 2025, the vesting occurred on Monday, March 31, 2025, the next business day.

F5 · derivative.expiration_date: On March 29, 2024, RSUs were granted and on March 29, 2025, one-third of these RSUs vested, with the remaining RSUs to vest on March 29, 2026, and March 29, 2027. Since the first anniversary of the date of grant was on Saturday, March 29, 2025, the vesting occurred on Monday, March 31, 2025, the next business day.

Read SEC document
March 31, 2025 Filed Apr 2, 2025 21:33 UTC Organon & Co. OGN · Entity 4115 GrantRestricted Stock Units · Derivative 50,369 $0.00 $0.00
Disclosure

SEC source: 0001859805-25-000004 · wk-form4_1743629588.xml · derivative · entry 8

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,369

Underlying: Common Stock · 50,369 shares

Expires not disclosed

F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock.

F4 · derivative.exercise_date: The Reporting Person was granted RSUs, which represent a contingent right to receive one share of Organon common stock for each RSU. On March 31, 2025, RSUs were granted and will vest in three equal installments on each of March 31, 2026, March 31, 2027, and March 31, 2028.

F4 · derivative.expiration_date: The Reporting Person was granted RSUs, which represent a contingent right to receive one share of Organon common stock for each RSU. On March 31, 2025, RSUs were granted and will vest in three equal installments on each of March 31, 2026, March 31, 2027, and March 31, 2028.

Read SEC document
March 31, 2025 Filed Apr 2, 2025 21:33 UTC Organon & Co. OGN · Entity 4115 GrantStock Option (right to buy) · Derivative 247,524 $0.00 Strike: $14.89 $0.00
Disclosure

SEC source: 0001859805-25-000004 · wk-form4_1743629588.xml · derivative · entry 7

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 247,524

Underlying: Common Stock · 247,524 shares

Expires not disclosed

F2 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2026, March 31, 2027, and March 31, 2028.

F2 · derivative.expiration_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2026, March 31, 2027, and March 31, 2028.

Read SEC document
March 31, 2025 Filed Apr 2, 2025 21:33 UTC Organon & Co. OGN · Entity 4115 Tax withholdingCommon Stock 1,713 $14.51 $24,855.63
Disclosure

SEC source: 0001859805-25-000004 · wk-form4_1743629588.xml · nonDerivative · entry 6

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 71,561.855

F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded.

Read SEC document
March 31, 2025 Filed Apr 2, 2025 21:33 UTC Organon & Co. OGN · Entity 4115 Exercise / conversionCommon Stock 3,937 $0.00 $0.00
Disclosure

SEC source: 0001859805-25-000004 · wk-form4_1743629588.xml · nonDerivative · entry 5

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,274.855

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 31, 2025 Filed Apr 2, 2025 21:33 UTC Organon & Co. OGN · Entity 4115 Tax withholdingCommon Stock 3,391 $14.51 $49,203.41
Disclosure

SEC source: 0001859805-25-000004 · wk-form4_1743629588.xml · nonDerivative · entry 4

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,337.855

F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded.

Read SEC document
March 31, 2025 Filed Apr 2, 2025 21:33 UTC Organon & Co. OGN · Entity 4115 Exercise / conversionCommon Stock 7,795 $0.00 $0.00
Disclosure

SEC source: 0001859805-25-000004 · wk-form4_1743629588.xml · nonDerivative · entry 3

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 72,728.855

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 31, 2025 Filed Apr 2, 2025 21:33 UTC Organon & Co. OGN · Entity 4115 Tax withholdingCommon Stock 4,241 $14.51 $61,536.91
Disclosure

SEC source: 0001859805-25-000004 · wk-form4_1743629588.xml · nonDerivative · entry 2

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,933.855

F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded.

Read SEC document
March 31, 2025 Filed Apr 2, 2025 21:33 UTC Organon & Co. OGN · Entity 4115 Exercise / conversionCommon Stock 9,751 $0.00 $0.00
Disclosure

SEC source: 0001859805-25-000004 · wk-form4_1743629588.xml · nonDerivative · entry 1

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,174.855

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 20, 2025 Filed Feb 24, 2025 22:01 UTC Organon & Co. OGN · Entity 4115 Tax withholdingCommon Stock 806 $15.29 $12,323.74
Disclosure

SEC source: 0001859805-25-000002 · wk-form4_1740434496.xml · nonDerivative · entry 4

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,423.855

F3 · balance_after: Includes the addition of 3,795.855 shares of Common Stock acquired from dividend reinvestments not previously reported.

Read SEC document
February 20, 2025 Filed Feb 24, 2025 22:01 UTC Organon & Co. OGN · Entity 4115 GrantCommon Stock 2,828 $0.00 $0.00
Disclosure

SEC source: 0001859805-25-000002 · wk-form4_1740434496.xml · nonDerivative · entry 3

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,434

F2 · shares: Represents the shares of Common Stock released to cover the dividend equivalents earned on the PSUs released above.

Read SEC document
February 20, 2025 Filed Feb 24, 2025 22:01 UTC Organon & Co. OGN · Entity 4115 Tax withholdingCommon Stock 4,703 $14.92 $70,168.76
Disclosure

SEC source: 0001859805-25-000002 · wk-form4_1740434496.xml · nonDerivative · entry 2

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,606

Read SEC document
February 20, 2025 Filed Feb 24, 2025 22:01 UTC Organon & Co. OGN · Entity 4115 GrantCommon Stock 15,441 $0.00 $0.00
Disclosure

SEC source: 0001859805-25-000002 · wk-form4_1740434496.xml · nonDerivative · entry 1

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,309

F1 · shares: Represents shares of Organon & Co. common stock ("Common Stock") for performance share units ("PSUs") granted to the reporting person on August 09, 2022 under the Organon & Co. 2021 Incentive Stock Plan. The performance-vesting restrictions with respect to these shares were released upon certification of performance goal attainment by the Talent Committee of Organon's Board of Directors.

Read SEC document
September 03, 2024 Filed Sep 5, 2024 20:30 UTC Organon & Co. OGN · Entity 4115 Tax withholdingCommon Stock 1,564 $20.35 $31,827.40
Disclosure

SEC source: 0001821825-24-000096 · wk-form4_1725568246.xml · nonDerivative · entry 2

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,868

Read SEC document
September 03, 2024 Filed Sep 5, 2024 20:30 UTC Organon & Co. OGN · Entity 4115 GrantCommon Stock 3,594 $0.00 $0.00
Disclosure

SEC source: 0001821825-24-000096 · wk-form4_1725568246.xml · nonDerivative · entry 1

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,432

F1 · shares: Represents shares of Organon & Co. common stock for performance share units granted to the reporting person on August 17, 2021 under the Organon & Co. 2021 Incentive Stock Plan. The performance-vesting restrictions with respect to these shares were released upon certification of performance goal attainment by the Talent Committee of Organon's Board of Directors.

Read SEC document
May 04, 2024 Filed May 7, 2024 20:07 UTC Organon & Co. OGN · Entity 4115 Exercise / conversionRestricted Stock Units · Derivative 3,604 $0.00 $0.00
Disclosure

SEC source: 0001821825-24-000065 · wk-form4_1715112429.xml · derivative · entry 3

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,604 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU.

F2 · derivative.exercise_date: On each of May 4, 2022, May 4, 2023 and May 4, 2024, one-third of the RSUs vested.

F2 · derivative.expiration_date: On each of May 4, 2022, May 4, 2023 and May 4, 2024, one-third of the RSUs vested.

Read SEC document
May 04, 2024 Filed May 7, 2024 20:07 UTC Organon & Co. OGN · Entity 4115 Tax withholdingCommon Stock 1,568 $19.61 $30,748.48
Disclosure

SEC source: 0001821825-24-000065 · wk-form4_1715112429.xml · nonDerivative · entry 2

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,838

Read SEC document
May 04, 2024 Filed May 7, 2024 20:07 UTC Organon & Co. OGN · Entity 4115 Exercise / conversionCommon Stock 3,604 $0.00 $0.00
Disclosure

SEC source: 0001821825-24-000065 · wk-form4_1715112429.xml · nonDerivative · entry 1

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,406

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 31, 2024 Filed Apr 3, 2024 22:42 UTC Organon & Co. OGN · Entity 4115 Exercise / conversionRestricted Stock Units · Derivative 7,794 $0.00 $0.00
Disclosure

SEC source: 0001821825-24-000051 · wk-form4_1712184144.xml · derivative · entry 6

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,590

Underlying: Common Stock · 7,794 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock.

F3 · derivative.exercise_date: On March 31, 2024, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2025 and March 31, 2026.

F3 · derivative.expiration_date: On March 31, 2024, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2025 and March 31, 2026.

Read SEC document
March 31, 2024 Filed Apr 3, 2024 22:42 UTC Organon & Co. OGN · Entity 4115 Exercise / conversionRestricted Stock Units · Derivative 3,936 $0.00 $0.00
Disclosure

SEC source: 0001821825-24-000051 · wk-form4_1712184144.xml · derivative · entry 5

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,937

Underlying: Common Stock · 3,936 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock.

F2 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon common stock for each RSU. On each of March 31, 2023, and March 31, 2024, one-third of the RSUs vested, with the remaining RSUs to vest on March 31, 2025.

F2 · derivative.expiration_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon common stock for each RSU. On each of March 31, 2023, and March 31, 2024, one-third of the RSUs vested, with the remaining RSUs to vest on March 31, 2025.

Read SEC document
March 31, 2024 Filed Apr 3, 2024 22:42 UTC Organon & Co. OGN · Entity 4115 Tax withholdingCommon Stock 2,328 $18.80 $43,766.40
Disclosure

SEC source: 0001821825-24-000051 · wk-form4_1712184144.xml · nonDerivative · entry 4

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,802

Read SEC document
March 31, 2024 Filed Apr 3, 2024 22:42 UTC Organon & Co. OGN · Entity 4115 Exercise / conversionCommon Stock 7,794 $0.00 $0.00
Disclosure

SEC source: 0001821825-24-000051 · wk-form4_1712184144.xml · nonDerivative · entry 3

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,130

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 31, 2024 Filed Apr 3, 2024 22:42 UTC Organon & Co. OGN · Entity 4115 Tax withholdingCommon Stock 1,712 $18.80 $32,185.60
Disclosure

SEC source: 0001821825-24-000051 · wk-form4_1712184144.xml · nonDerivative · entry 2

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,336

Read SEC document
March 31, 2024 Filed Apr 3, 2024 22:42 UTC Organon & Co. OGN · Entity 4115 Exercise / conversionCommon Stock 3,936 $0.00 $0.00
Disclosure

SEC source: 0001821825-24-000051 · wk-form4_1712184144.xml · nonDerivative · entry 1

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,048

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 29, 2024 Filed Apr 2, 2024 20:24 UTC Organon & Co. OGN · Entity 4115 GrantStock Option (right to buy) · Derivative 119,825 $0.00 Strike: $18.80 $0.00
Disclosure

SEC source: 0001821825-24-000026 · wk-form4_1712089486.xml · derivative · entry 2

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 119,825

Underlying: Common Stock · 119,825 shares

Expires 2027-03-29

F3 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027.

Read SEC document
March 29, 2024 Filed Apr 2, 2024 20:24 UTC Organon & Co. OGN · Entity 4115 GrantRestricted Stock Units · Derivative 29,255 $0.00 $0.00
Disclosure

SEC source: 0001821825-24-000026 · wk-form4_1712089486.xml · derivative · entry 1

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,255

Underlying: Common Stock · 29,255 shares

Expires 2027-03-29

F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU.

F2 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027.

Read SEC document
February 28, 2024 Filed Mar 1, 2024 21:23 UTC Organon & Co. OGN · Entity 4115 Exercise / conversionRestricted Stock Units · Derivative 14,319 $0.00 $0.00
Disclosure

SEC source: 0001821825-24-000008 · wk-form4_1709328178.xml · derivative · entry 3

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,319 shares

Expires 2023-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. common stock.

F2 · date: As previously reported, these Restricted Stock Units vested on December 31, 2023, and shares of Organon & Co. common stock were distributed to the Reporting Person on February 28, 2024.

F2 · derivative.exercise_date: As previously reported, these Restricted Stock Units vested on December 31, 2023, and shares of Organon & Co. common stock were distributed to the Reporting Person on February 28, 2024.

F2 · derivative.expiration_date: As previously reported, these Restricted Stock Units vested on December 31, 2023, and shares of Organon & Co. common stock were distributed to the Reporting Person on February 28, 2024.

Read SEC document
February 28, 2024 Filed Mar 1, 2024 21:23 UTC Organon & Co. OGN · Entity 4115 Tax withholdingCommon Stock 4,223 $18.04 $76,182.92
Disclosure

SEC source: 0001821825-24-000008 · wk-form4_1709328178.xml · nonDerivative · entry 2

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,112

Read SEC document
February 28, 2024 Filed Mar 1, 2024 21:23 UTC Organon & Co. OGN · Entity 4115 Exercise / conversionCommon Stock 14,319 Not disclosed Not disclosed
Disclosure

SEC source: 0001821825-24-000008 · wk-form4_1709328178.xml · nonDerivative · entry 1

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,335

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit converts into one share of Organon & Co. common stock.

Read SEC document
May 04, 2023 Filed May 8, 2023 22:44 UTC Organon & Co. OGN · Entity 4115 Exercise / conversionRestricted Stock Units · Derivative 3,599 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-028101 · doc4.xml · derivative · entry 3

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,604

Underlying: Common Stock · 3,599 shares

Expires 2024-05-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024.

F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024.

F1 · derivative.expiration_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024.

Read SEC document
May 04, 2023 Filed May 8, 2023 22:44 UTC Organon & Co. OGN · Entity 4115 Tax withholdingCommon Stock 1,162 $24.24 $28,166.88
Disclosure

SEC source: 0001209191-23-028101 · doc4.xml · nonDerivative · entry 2

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,016

Read SEC document
May 04, 2023 Filed May 8, 2023 22:44 UTC Organon & Co. OGN · Entity 4115 Exercise / conversionCommon Stock 3,599 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-028101 · doc4.xml · nonDerivative · entry 1

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,178

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024.

Read SEC document
May 01, 2023 Filed May 3, 2023 23:07 UTC Organon & Co. OGN · Entity 4115 Exercise / conversionRestricted Stock Units · Derivative 1,490 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001209191-23-027174 · doc4.xml · derivative · entry 3

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,490 shares

Expires 2023-05-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested, and on May 1, 2023, the remaining 50% of the RSUs vested.

F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested, and on May 1, 2023, the remaining 50% of the RSUs vested.

F1 · derivative.expiration_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested, and on May 1, 2023, the remaining 50% of the RSUs vested.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.